Li, Yue
Chen, Baili
Gao, Xiang
Hu, Naizhong
Huang, Meifang
Ran, Zhihua
Liu, Zhanju
Zhong, Jie
Zou, Duowu
Wu, Xiaoping
Ren, Jianlin
Sheng, Jianqiu
Zheng, Ping
Wang, Huahong
Chen, Minhu
Chen, Junrong
Xi, Peng
Lu, Jiajia
Handel, Malcolm
Liu, Yanfang
Fan, Hua
Qian, Jiaming
Funding for this research was provided by:
Xi’an Janssen Pharmaceutical Ltd., Beijing, China (-)
Article History
Received: 19 February 2019
Accepted: 29 July 2019
First Online: 16 August 2019
Ethics approval and consent to participate
: This study was conducted in accordance with the ethical principles originating in the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. The Institutional Review Board at each study site approved the trial design.(see the REMICADECRD4018 CSR IRB-IEC List).All the eligible patients provided written informed consent before participating in the study.
: Not applicable.
: This work was supported by Xi’an Janssen Pharmaceutical Ltd., Beijing, China. The funding body had a role in data analysis and data interpretation. No other competing interests exist.